Changes of Cerebral Spinal Fluid APPSα Levels Under Oral Therapy With Acitretin 30 mg Daily in Patients With Mild to Moderate Alzheimer's Disease: a Multicenter Prospective Randomised Placebo-controlled Parallel-group Study. [Veränderungen der APPSα -Konzentration in der Zerebrospinalflüssigkeit nach der oralen Therapie mit 30 mg Acitretin täglich bei Patienten mit leichter bis mittelschwerer Alzheimer-Krankheit: multizentrische prospektive randomisierte placebo-kontrollierte Studie mit Parallelgruppen-Design.]

Trial Profile

Changes of Cerebral Spinal Fluid APPSα Levels Under Oral Therapy With Acitretin 30 mg Daily in Patients With Mild to Moderate Alzheimer's Disease: a Multicenter Prospective Randomised Placebo-controlled Parallel-group Study. [Veränderungen der APPSα -Konzentration in der Zerebrospinalflüssigkeit nach der oralen Therapie mit 30 mg Acitretin täglich bei Patienten mit leichter bis mittelschwerer Alzheimer-Krankheit: multizentrische prospektive randomisierte placebo-kontrollierte Studie mit Parallelgruppen-Design.]

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Acitretin (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Acronyms ADAM
  • Most Recent Events

    • 15 May 2013 Status changed from recruiting to completed as reported by European Clinical Trials Database.
    • 21 Apr 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2009-011881-27).
    • 20 Jul 2011 Results presented at the 2011 International Conference on Alzheimer's Disease.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top